Fig. 1
IL-2 treatment enhanced the pro-apoptotic effects of sorafenib. a, b Cell viability was measured via MTT assay in HepG2 cells and Huh7 cells. The different doses of IL-2 were added in the presence of 5 μM sorafenib. c, d Cell death was evaluated via LDH release assay in HepG2 cells and Huh7 cells. The different doses of IL-2 were added in the presence of 5 μM sorafenib. e–g A TUNEL assay was performed to observe the cell apoptotic rate. IL-2 (5 ng/ml) treatment was carried out in the presence of 5 μM sorafenib. h, i Caspase-3 activity was measured in HepG2 cells and Huh7 cells. IL-2 (5 ng/ml) treatment was carried out in the presence of 5 μM sorafenib. *P < 0.05 vs. control group; #P < 0.05 vs. sorafenib group. Cont control